New Pill Reduces ‘Bad’ Cholesterol Levels by Almost 60%

Health & LifestyleNews
360

Listen to article (english)

Translate to Spanish or other 102 languages!

The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol. Image for illustration purposes
The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

A recent study published in JAMA on November 9, investigates a drug called enlicitide. 

The study recruited people with heterozygous familial hypercholesterolemia, a genetic condition that causes the individual to have high levels of LDL, or “bad” cholesterol.

- Advertisement -

For these individuals, lifestyle changes and statins are often inadequate to bring their levels of LDL cholesterol down.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/oral-pill-enlicitide-reduces-bad-cholesterol-levels-statins?utm_term=feature&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2025-11-26&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

Information source: https://www.medicalnewstoday.com

- Advertisement -

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Importance of Knowing Family Health History
Next article
DHR Health Earns an ‘A’ Hospital Safety Grade

More Articles

STHS Dedicating Latest “South Texas Healthy Living” Episode to Arthritis Education, July 26th

More than 58 million U.S. adults are living with doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention (CDC), making it the nation’s leading cause of disability.

No More Needles: FDA Approves First Daily Pill to Replace Injectable Cholesterol Drugs

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). Image source: Merck.com.

Physicians Warn of Rising ER Visits Linked to E-Bikes and Scooters

Mega Doctor News CLEVELAND CLINIC - As electric bikes and scooters grow in...

STHS Heart Ranks Among Nation’s Top Hospitals for Heart Attack Care

Every year, more than 800,000 people in the United States suffer a heart attack, according to the Centers for Disease Control and Prevention, an event that occurs approximately every 40 seconds.
- Advertisement -